Share Name Share Symbol Market Type Share ISIN Share Description
Epistem LSE:EHP London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 85.00p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.7 -3.4 -30.2 - 15.89

Epistem (EHP) Latest News

More Epistem News
Epistem Takeover Rumours

Epistem (EHP) Share Charts

1 Year Epistem Chart

1 Year Epistem Chart

1 Month Epistem Chart

1 Month Epistem Chart

Intraday Epistem Chart

Intraday Epistem Chart

Epistem (EHP) Discussions and Chat

Epistem (EHP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Epistem trades in real-time

Epistem (EHP) Top Chat Posts

DateSubject
02/4/2015
17:37
bigman: Big deal directors bought a few hundred pounds of shares in options... clearly they don't think it worth investing a few grand. I think Chairman David Evans will be having a few sleepless nights as over at EKF where he is Executive Chairman they are having a few problems and now undertaking a "strategic review" by independent directors, and the share price there has been falling quiet sharply.
24/10/2013
09:29
asph: seems total panic hit share price --- considering adding now for early gain to equalise this years changes !
05/7/2012
07:16
ladyfarmer: Great news! How many TB tests in India? Epistem Holdings plc Tuberculosis test gains CE-IVD registration Date : 05/07/2012 @ 07:00 Source : UK Regulatory (RNS & others) Stock : Epistem (EHP) Quote : 400.0 0.0 (0.00%) @ 05:00 HOME » LSE » E » Epistem share price Free Epistem Annual Company Report Epistem Holdings plc Tuberculosis test gains CE-IVD registration Share this article PrintAlert TIDMEHP RNS Number : 9465G Epistem Holdings plc 05 July 2012 Epistem Plc ("Epistem" or "the Company") Epistem Tuberculosis test gains CE-IVD registration Epistem (London AIM:EHP), the biotechnology and personalised medicine company, is pleased to announce the registration of its rapid molecular test for Tuberculosis (TB) test as a CE Marked in-vitro diagnostic medical device (CE-IVD). The registration enables Epistem and/or its authorised representatives to place its TB test and Genedrive(TM)units for sale in the EEA member state markets. Genedrive(TM) provides a major advance in next generation molecular diagnostic testing by providing a rapid (30 minute), low cost, simple to use 'Point of Care' device with high sensitivity and specificity. Genedrive(TM) has applications across a wide range of bacterial, viral and fungal and somatic mutation disease status. Genedrive(TM) will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively with traditional less reliable methods of diagnosis such as microscopy and culturing. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs. On the back of this CE-IVD registration, Epistem is now preparing regulatory submissions for India in advance of the anticipated launch of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year. India has the largest number of TB sufferers in the world, more than twice the number in China, which has the second highest infection rate. According to the WHO, every year 2 million new patients in India develop TB, with the highest incidence of fatalities occurring in remote rural areas. Commenting on the successful registration of Epistem's first Genedrive(TM) test, Matthew Walls, CEO said "This is an important milestone for the Company as we move towards our first significant revenue stream in the commercialization of Genedrive(TM)" For further information contact: Epistem Plc Matthew Walls, Chief Executive Officer ++44 161 606 7258 Peel Hunt LLP Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900 De Facto Financial Mike Wort/Anna Dunphy ++44207 556 1063 Notes for editors Epistem is a biotechnology company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive(TM)) alongside contract research services to drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel and proprietary next generation molecular biology for use in personalised medicine. www.epistem.co.uk This information is provided by RNS The company news service from the London Stock Exchange END MSCSSUFILFESEIW Epistem (LSE:EHP) Historical Stock Chart 1 Year : From Jul 2011 to Jul 2012 Epistem (LSE:EHP) Intraday Stock Chart Today : Thursday 5 July 2012
05/7/2012
07:16
ladyfarmer: Great news! How many TB tests in India? Epistem Holdings plc Tuberculosis test gains CE-IVD registration Date : 05/07/2012 @ 07:00 Source : UK Regulatory (RNS & others) Stock : Epistem (EHP) Quote : 400.0 0.0 (0.00%) @ 05:00 HOME » LSE » E » Epistem share price Free Epistem Annual Company Report Epistem Holdings plc Tuberculosis test gains CE-IVD registration Share this article PrintAlert TIDMEHP RNS Number : 9465G Epistem Holdings plc 05 July 2012 Epistem Plc ("Epistem" or "the Company") Epistem Tuberculosis test gains CE-IVD registration Epistem (London AIM:EHP), the biotechnology and personalised medicine company, is pleased to announce the registration of its rapid molecular test for Tuberculosis (TB) test as a CE Marked in-vitro diagnostic medical device (CE-IVD). The registration enables Epistem and/or its authorised representatives to place its TB test and Genedrive(TM)units for sale in the EEA member state markets. Genedrive(TM) provides a major advance in next generation molecular diagnostic testing by providing a rapid (30 minute), low cost, simple to use 'Point of Care' device with high sensitivity and specificity. Genedrive(TM) has applications across a wide range of bacterial, viral and fungal and somatic mutation disease status. Genedrive(TM) will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively with traditional less reliable methods of diagnosis such as microscopy and culturing. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs. On the back of this CE-IVD registration, Epistem is now preparing regulatory submissions for India in advance of the anticipated launch of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year. India has the largest number of TB sufferers in the world, more than twice the number in China, which has the second highest infection rate. According to the WHO, every year 2 million new patients in India develop TB, with the highest incidence of fatalities occurring in remote rural areas. Commenting on the successful registration of Epistem's first Genedrive(TM) test, Matthew Walls, CEO said "This is an important milestone for the Company as we move towards our first significant revenue stream in the commercialization of Genedrive(TM)" For further information contact: Epistem Plc Matthew Walls, Chief Executive Officer ++44 161 606 7258 Peel Hunt LLP Nominated Adviser: James Steel/Vijay Barathan ++44 207 418 8900 De Facto Financial Mike Wort/Anna Dunphy ++44207 556 1063
20/11/2009
11:17
yuka: See they have just done a placing of new shares at 400 to raise more money for furthe expansion. Share price taken it rather well. Onward and upward. £10 by Christmas :)
16/3/2009
09:15
yuka: Well where are all the rampers when you need them? Share price has gone to sleep the last few days.
Epistem share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20161206 14:01:59